Gerald Spöttl

961 total citations
25 papers, 775 citations indexed

About

Gerald Spöttl is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Gerald Spöttl has authored 25 papers receiving a total of 775 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 14 papers in Epidemiology and 10 papers in Molecular Biology. Recurrent topics in Gerald Spöttl's work include Neuroendocrine Tumor Research Advances (13 papers), Neuroblastoma Research and Treatments (9 papers) and Lung Cancer Research Studies (7 papers). Gerald Spöttl is often cited by papers focused on Neuroendocrine Tumor Research Advances (13 papers), Neuroblastoma Research and Treatments (9 papers) and Lung Cancer Research Studies (7 papers). Gerald Spöttl collaborates with scholars based in Germany, Switzerland and United Kingdom. Gerald Spöttl's co-authors include Christoph J. Auernhammer, Burkhard Göke, Kathrin Zitzmann, Stephan Brand, Svenja Nölting, Enrico N. De Toni, Julian Maurer, Heinrich H.D. Meyer, K. Mann and Bernhard Saller and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.

In The Last Decade

Gerald Spöttl

25 papers receiving 756 citations

Peers

Gerald Spöttl

ONCOL

EPIDE

NEURO

IMMUN

Stanley Frankel United States

Andrea Lamprecht Austria

Tjoung‐Won Park Germany

K Rygaard Denmark

David Z. Chang United States

Sunita Badola United States

Rhona J. McVey United Kingdom

C. De Micco France

Junichi Ueyama Japan

Hong Bu China

Stanley Frankel United States

Gerald Spöttl

424 ×1.1

ONCOL

90 ×0.3

EPIDE

514 ×1.7

73 ×0.4

NEURO

196 ×1.5

IMMUN

Citations per year, relative to Gerald Spöttl Gerald Spöttl (= 1×) peers Stanley Frankel

Countries citing papers authored by Gerald Spöttl

Since Specialization

Citations

This map shows the geographic impact of Gerald Spöttl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Spöttl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Spöttl more than expected).

Fields of papers citing papers by Gerald Spöttl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Spöttl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Spöttl. The network helps show where Gerald Spöttl may publish in the future.

Co-authorship network of co-authors of Gerald Spöttl

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Spöttl. A scholar is included among the top collaborators of Gerald Spöttl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Spöttl. Gerald Spöttl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spöttl, Gerald, et al.. (2021). Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Cancers. 13(6). 1485–1485. 6 indexed citations

Auernhammer, Christoph J., Harun Ilhan, Simon Lindner, et al.. (2019). Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. Journal of Nuclear Medicine. 60(9). 1240–1246. 36 indexed citations

Spöttl, Gerald, Julian Maurer, Michael Lauseker, et al.. (2018). The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. Endocrine Related Cancer. 25(10). 893–908. 19 indexed citations

Knösel, Thomas, Svenja Nölting, Gerald Spöttl, et al.. (2018). Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. Endocrine Related Cancer. 25(5). 547–560. 6 indexed citations

Orth, Michael, et al.. (2017). The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells. PLoS ONE. 12(5). e0178375–e0178375. 9 indexed citations

Nölting, Svenja, Sabine Herterich, Stefanie Hahner, et al.. (2016). The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53<sup>wild type</sup> Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology. 106(1). 1–19. 25 indexed citations

Spampatti, Matilde Pia, George Vlotides, Gerald Spöttl, et al.. (2015). Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for ‘Off-Target' Effects Not Mediated by c-Met Inhibition. Neuroendocrinology. 103(3-4). 383–401. 17 indexed citations

Nölting, Svenja, Julian Maurer, Gerald Spöttl, et al.. (2015). Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. PLoS ONE. 10(12). e0143830–e0143830. 16 indexed citations

Zitzmann, Kathrin, George Vlotides, Gerald Spöttl, et al.. (2013). The Novel Somatostatin Receptor 2/Dopamine Type 2 Receptor Chimeric Compound BIM-23A758 Decreases the Viability of Human GOT1 Midgut Carcinoid Cells. Neuroendocrinology. 98(2). 128–136. 14 indexed citations

10.

Zitzmann, Kathrin, George Vlotides, Stephan Brand, et al.. (2012). Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocrine Related Cancer. 19(3). 423–434. 26 indexed citations

11.

Zitzmann, Kathrin, et al.. (2010). Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Letters. 295(1). 100–109. 114 indexed citations

12.

Fottner, Christian, et al.. (2008). Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers α-fetoprotein and human chorionic gonadotropin. European Journal of Endocrinology. 159(3). 317–327. 10 indexed citations

13.

Zitzmann, Kathrin, Enrico N. De Toni, Stephan Brand, et al.. (2007). The Novel mTOR Inhibitor RAD001 (Everolimus) Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells. Neuroendocrinology. 85(1). 54–60. 133 indexed citations

14.

Zitzmann, Kathrin, et al.. (2006). Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells. Biochemical and Biophysical Research Communications. 344(4). 1334–1341. 100 indexed citations

15.

Weber, Matthias M., et al.. (1999). Characterization of Human Insulin-Like Growth Factor-Binding Proteins by Two-Dimensional Polyacrylamide Gel Electrophoresis and Western Ligand Blot Analysis¹. The Journal of Clinical Endocrinology & Metabolism. 84(5). 1679–1684. 19 indexed citations

16.

Dirnhofer, S, S. Madersbacher, Gerald Spöttl, et al.. (1994). The molecular basis for epitopes on the free β-subunit of human chorionic gonadotrophin (hCG), its carboxyl-terminal peptide and the hCGβ-core fragment. Journal of Endocrinology. 141(1). 153–162. 35 indexed citations

17.

Berger, Patrick, S. Schwarz, Gerald Spöttl, Georg Wick, & Karl Mann. (1993). Variants of human chorionic gonadotropin from pregnant women and tumor patients recognized by monoclonal antibodies.. The Journal of Clinical Endocrinology & Metabolism. 77(2). 347–351. 29 indexed citations

18.

Luppa, Peter B., Gerald Spöttl, Bernhard Saller, D. Neumeier, & K. Mann. (1992). Cross‐reactivity of a commercial chemiluminescence immunoassay for human chorionic gonadotropin with the free β‐subunit. Journal of Bioluminescence and Chemiluminescence. 7(3). 195–201. 1 indexed citations

19.

Saller, Bernhard, et al.. (1990). Testicular cancer secretes intact human choriogonadotropin (hCG) and its free beta-subunit: evidence that hCG (+hCG-beta) assays are the most reliable in diagnosis and follow-up. Clinical Chemistry. 36(2). 234–239. 49 indexed citations

20.

Mann, Kenneth G., Wolfgang E. Merz, Ulrich Markel, Gerald Spöttl, & Barbara Pütz. (1985). Acid isoelectric variants of hCG in patients with testicular cancer: Isolation and characterization by neuraminidase digestion. European Journal of Endocrinology. 110(1_Suppla). S154–S155. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact